Business Context and Reporting Period
This Form 8-K Current Report was filed by Aprea Therapeutics, Inc. on August 28, 2026. The registrant is a Delaware corporation with its principal executive offices in Doylestown, PA. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol APRE.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Under Item 8.01 (Other Events), the company announced the expansion of its intellectual property portfolio for its precision oncology programs. No financial material changes were reported in this document.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) detailing the IP expansion but does not include specific management commentary, financial guidance, or a discussion of risks and contingencies within the body of the 8-K. The company is not currently designated as an emerging growth company in this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific details on the new intellectual property assets and their potential impact on the precision oncology pipeline.
- Verify the status of the company's cash runway and liquidity in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Confirm whether the IP expansion affects any existing regulatory filings or clinical trial timelines.